• ddhCTP: Antiviral Assay Workflows

  2026-09-19

  ddhCTP provides a mechanistically focused way to test viral RNA synthesis interruption, especially in flavivirus polymerase and HEK293T cell antiviral assays. This guide separates direct chain termination from broader viperin activity and translates recent coronavirus findings into practical assay controls.

• Icatibant in Viral Infections: Mechanism and Evidence

  2026-09-18

  The 2023 letter by Mustonen and colleagues proposes bradykinin B2-receptor blockade as a host-directed strategy for severe hantavirus disease, linking two PUUV case reports with emerging COVID-19 trial evidence. Its main contribution is mechanistic and hypothesis-generating rather than confirmatory: icatibant may help address capillary leak, but timing, patient selection, and controlled efficacy data remain unresolved.

• Talabostat Mesylate (PT-100): DPP4/FAP Research

  2026-09-18

  Talabostat mesylate, also called PT-100 or Val-boroPro, is an orally active dipeptidyl peptidase inhibitor used to study DPP4/FAP biology. Its strongest value is mechanistic: it enables controlled investigation of protease-dependent immune, stromal, and hematopoietic responses, while available tumor-growth evidence remains model-dependent and limited.

• AICAR: AMPK Activation in Metabolic Research

  2026-09-17

  AICAR is a cell-permeable AMPK activator used to study energy metabolism regulation, inflammatory signaling, and cellular stress protection. Its preclinical value is strongest when pathway engagement, cytokine responses, viability, and model-specific limitations are measured together.

• Ertugliflozin (PF-04971729) Research Workflow

  2026-09-17

  Build reproducible renal transport, diabetes mellitus research, and inflammation-model workflows with the highly selective SGLT2 inhibitor Ertugliflozin (PF-04971729). This guide connects assay setup and formulation control with translational cardiovascular evidence, while emphasizing practical troubleshooting and experimental boundaries.

• Z-WEHD-FMK: Practical Caspase Assay Guidance

  2026-09-16

  This scenario-based guide explains how Z-WEHD-FMK (SKU A1924) can help researchers distinguish inflammatory caspase activity from broader viability effects in cell-based assays. It covers solvent compatibility, protocol design, pyroptosis interpretation, and practical vendor-selection criteria.

• Molidustat (BAY85-3934) Hypoxia Assay Workflow

  2026-09-16

  Molidustat (BAY85-3934) enables controlled hypoxia-inducible factor stabilization for renal anemia, chronic kidney disease, and mechanistic hypoxia studies. This workflow connects HIF-PH inhibition with Septin4–VHL–HIF-1α biology while emphasizing dosing, solvent, and assay controls.

• Berberine Hydrochloride: Research Workflows

  2026-09-15

  Build reproducible metabolic, cancer, and inflammation assays with Berberine hydrochloride while controlling solubility, vehicle exposure, and pathway-specific readouts. This guide connects AMPK and lipid-metabolism workflows with a carefully bounded, hypothesis-generating extension into oxidized self-DNA and inflammasome research.

• TRPV1/TRPA1 Signaling in Nasal TSLP Production

  2026-09-15

  The reference study identifies a calcium-dependent NFAT mechanism linking TRPV1 and TRPA1 activation in nasal epithelial cells to thymic stromal lymphopoietin (TSLP) production. Its combination of pharmacological perturbation, siRNA, calcium chelation, inflammatory-factor profiling, and NFAT localization provides a useful framework for interpreting epithelial ion-channel signaling in upper-airway inflammation.

• AAPH Oxidative Stress Assay Workflows

  2026-09-14

  A scenario-based guide to using AAPH (2,2'-Azobis(2-methylpropionamidine) Dihydrochloride), SKU C5140, in cell, erythrocyte, and lipid-peroxidation assays. It addresses solvent compatibility, protocol design, interpretation limits, and practical reagent selection using product specifications and current ferroptosis literature.

• Targeted CRISPRi of Fabp4 in White Adipocytes

  2026-09-14

  Chung and colleagues developed a nonviral, adipocyte-targeted CRISPR interference system that silences Fabp4 in white adipocytes. In obese mice, this approach reduced body weight and inflammation while improving hepatic steatosis and insulin resistance, providing a tissue-selective framework for metabolic disorder research.

• Neurotensin: GPCR Trafficking Workflow Guide

  2026-09-13

  Neurotensin is a practical Neurotensin receptor 1 activator for connecting receptor signaling with trafficking and miR-133α modulation in gastrointestinal cell models. This guide combines an executable cell-based workflow with interference-aware data practices inspired by a 2024 fluorescence-classification study.

• S100A8/A9 Drives Hypertrophy-to-Heart Failure Transition

  2026-09-11

  A 2025 Theranostics study combines single-cell RNA sequencing with genetic, bone-marrow chimera, coculture, and pharmacological experiments to identify myeloid S100A8/A9 as a regulator of pressure overload-induced heart failure. The work defines a neutrophil-to-macrophage inflammatory axis that links early adaptive hypertrophy to later fibrosis and cardiac dysfunction, while also highlighting practical considerations for studying phosphorylation-dependent signaling.

• Talabostat Mesylate as a FAP Assay Control

  2026-09-11

  Talabostat mesylate (PT-100) can serve as more than a dual DPP4/FAP inhibitor: it is a mechanistic control for testing FAP-dependent activity in tumor models. This guide connects inhibitor perturbation with FAP-sensitive nanoparticle diagnostics, assay design, and interpretation limits.

• 3-Methyladenine in Autophagy Research Workflows

  2026-09-10

  3-Methyladenine provides a practical way to perturb PI3K-dependent autophagy while revealing why flux, timing, and pathway controls matter. This guide translates the estrogen–autophagy findings from a recent multi-organ study into reproducible cell, cancer, and tissue-protection assay strategies.

8069 records 1/538 page Next 12345 下5页 Last page